Immunocore price target lowered to $74 from $80 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Immunocore to $74 from $80 and keeps an Overweight rating on the shares. The firm’s estimates are in line to slightly below consensus on Kimmtrak revenues and following the recent brenetafusp Phase 1 data in ovarian cancer presented at ESMO, it would listen for management commentary ahead of the non-small cell lung carcinoma data expected by Q4, the analyst tells investors in a preview note.